Меню
Идёт набор NCT07225426

Personalizing Financial Incentives

Без фазы С лечением Obesity & Overweight

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: personalized financial incentives.
Кому может быть актуально
Состояния в реестре: Obesity & Overweight. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Log2LoseAI: Reinforcement Learning to Create a Framework for Personalizing Financial Incentives

Обзор

The purpose of this study is to determine the feasibility of providing personalized incentives for dietary self-monitoring and/or interim weight loss to people enrolled in a weight-loss program

Подробное описание

In this study, community outpatients will participate in a clinician-facilitated, group-based behavioral weight-loss program for 24 weeks. Dietary self-monitoring data (input by patients via a mobile phone dietary application) and weight data (input by patients via cellular scale) will be collected by a software platform. A reinforcement learning algorithm will use data collected during the trial to predict which participants will respond to a financial incentive. Incentives will be provided to participants predicted to respond, and they will be notified of incentives via text messaging.

Вмешательства

  • Поведенческое personalized financial incentives
    Every week, a reinforcement learning algorithm will process data on weight loss, calorie logging, and incentives earned to predict that their weight loss is positively influenced by incentives.

Первичные конечные точки

  • Screening-to-enrollment ratio [Срок оценки: Week 0]
  • Retention for outcomes [Срок оценки: 25 weeks]
Вторичные конечные точки (3)
  • Adherence to calorie logging [Срок оценки: 24 weeks]
  • Adherence to self-weighing [Срок оценки: 24 weeks]
  • Body weight [Срок оценки: baseline to 25 weeks]

Критерии участия

Критерии включения

  • Willing to attend virtual baseline and follow-up data collection visits
  • At least 18 years of age
  • Verified obesity as defined as a BMI ≥30 kg/m2
  • Agree to attend 13 biweekly group classes (virtual) delivered by a registered dietitian
  • Agree to review study materials between classes
  • Regular access to an unshared smart phone
  • Reliable access to internet
  • Able to speak and read English
  • Desire to lose weight
  • Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
  • Ability to download and use Fitbit app daily
  • Have or be willing to create a Gmail address
  • Physical ability to stand on a scale without support

Критерии исключения

  • Weight loss of at least 10lbs in the month prior to screening
  • Weight > 380lbs
  • Currently enrolled or enrolled in the previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
  • New user of weight loss medication
  • Pregnant, lactating or planning on becoming pregnant during the study
  • History of bariatric procedure or planning to have bariatric procedure in the study timeframe
  • Residing in a nursing home, skilled nursing facility or assisted living facility
  • Impaired hearing
  • Significant dementia, drug or alcohol abuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
  • Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
  • Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
  • Diuretic medication doses higher than hydrochlorothiazide or chlorthalidone 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
  • Unstable heart disease in the 6 months prior to screening
  • Chronic kidney disease at stage 4 or higher
  • Exertional chest pain
  • Pain, fainting, or other conditions that prohibit mild/moderate exercise
  • History of ascites requiring paracentesis
  • Inducing vomiting to prevent weight gain or counteract the effects of eating an average of 1 time per week or more in the past 3 months\*
  • Not suitable for study participation due to other reasons at the discretion of the investigators

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • University of Utah — Salt Lake City

Идентификаторы

NCT: NCT07225426 · 00188990 · R34HL170205

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗